ATXS (Astria Therapeutics) Total Assets : $342.36 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics Total Assets?

Astria Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $342.36 Mil.

During the past 12 months, Astria Therapeutics's average Total Assets Growth Rate was 74.90% per year. During the past 3 years, the average Total Assets Growth Rate was 92.10% per year. During the past 5 years, the average Total Assets Growth Rate was 29.20% per year. During the past 10 years, the average Total Assets Growth Rate was 23.00% per year.

During the past 12 years, Astria Therapeutics's highest 3-Year average Total Assets Growth Rate was 92.10%. The lowest was -8.80%. And the median was 18.20%.

Total Assets is connected with ROA %. Astria Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -29.12%. Total Assets is also linked to Revenue through Asset Turnover. Astria Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Astria Therapeutics Total Assets Historical Data

The historical data trend for Astria Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics Total Assets Chart

Astria Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

47.46

127.51

230.63

254.67

342.36

Astria Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															254.67	378.81	367.99	361.64	342.36

Astria Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Astria Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	319.263	+	23.1
	=	342.36

Astria Therapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	319.263	+	23.1
	=	342.36

Astria Therapeutics (NAS:ATXS) Total Assets Explanation

Total Assets is connected with ROA %.

Astria Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-102.504	/	( (361.639	+	342.363)	/ 2 )
	=	-102.504	/	352.001
	=	-29.12 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Astria Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	0	/	( (361.639	+	342.363)	/ 2 )
=	0	/	352.001
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Astria Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Astria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Boston Wharf Road, 10th Floor, Boston, MA, USA, 02210

Website

https://www.astriatx.com

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Executives

Christopher Morabito	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews	officer: Chief Business Officer	C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Andrew Komjathy	officer: Chief Commercial Officer	CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols	officer: Chief Scientific Officer	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp	director, 10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck	director	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole	director	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger	officer: Secretary and General Counsel	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142